Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jenette Swisher

Internal Medicine Hickory, NC Medical Doctor

NPI 1295757318 CMS profile 194198

915 Tate Blvd Se, Suite 170, Hickory, NC 28602

Open in the dashboard

General payments

$10,533

508 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenette Swisher of Hickory, NC is reported in the CMS Open Payments database as having received $10,533 across 508 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,580 23
2024 General $417 9
2023 General $1,238 56
2022 General $1,480 89
2021 General $1,773 105
2020 General $1,385 79
2019 General $1,660 147

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenette Swisher
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jenette Swisher were reported at $2,580. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jenette Swisher Internal Medicine median Middle half National median
2019 $1,660 $159 $48–$570 $163
2020 $1,385 $119 $33–$402 $114
2021 $1,773 $135 $37–$521 $132
2022 $1,480 $141 $42–$496 $149
2023 $1,238 $149 $45–$519 $160
2024 $417 $154 $47–$537 $164
2025 $2,580 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $2,451 25 payments
  2. AstraZeneca Pharmaceuticals LP $1,580 36 payments
  3. AbbVie, Inc. $1,251 50 payments
  4. Novo Nordisk Inc $918 99 payments
  5. Lilly USA, LLC $668 49 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $497 57 payments
  7. Amgen Inc. $381 25 payments
  8. Pfizer Inc. $274 18 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $242 17 payments
  10. Sanofi-Aventis U.S. LLC $233 12 payments
  11. Other $2,037 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,365 505 payments
  2. Travel and Lodging $1,149 1 payment
  3. Education $18 2 payments
Products named General payments · program years 2019–2025
  1. Xeomin $2,451 25 payments
  2. FARXIGA $1,422 25 payments
  3. BREZTRI $629 14 payments
  4. BOTOX $562 10 payments
  5. JARDIANCE Diabetes $477 56 payments
  6. Ozempic $455 48 payments
  7. Saxenda $304 36 payments
  8. TRULICITY $300 20 payments
  9. RYBELSUS $296 24 payments
  10. JARDIANCE Diabetes $263 18 payments
  11. Other $5,034 346 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

55

Median for Internal Medicine: 777

Drug cost

$962

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 20 $351
Simvastatin Generic 21 $318
Donepezil Hcl Generic 14 $294

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $232
$232 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

508 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record